Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease

Journal of Neurophysiology

Volumn 92, Issue 5, 2004, Pages 2738-2746

  Li, Lijun ^a,b   Murphy, Timothy H ^a,b   Hayden, Michael R ^a,b   Raymond, Lynn A ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; HUNTINGTIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POLYGLUTAMINE; AMPA RECEPTOR; HD PROTEIN, HUMAN; HDH PROTEIN, MOUSE; NERVE PROTEIN; NR2B NMDA RECEPTOR; NUCLEAR PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DEGENERATIVE DISEASE; EXCITOTOXICITY; HUNTINGTON CHOREA; MOUSE; NERVE CELL DEGENERATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; SYNAPSE; ANIMAL; CORPUS STRIATUM; DISEASE MODEL; ELECTROSTIMULATION; GENETICS; HUMAN; METABOLISM; MOUSE STRAIN; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TRINUCLEOTIDE REPEAT;

ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION; HUMANS; HUNTINGTON DISEASE; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPSES; TRINUCLEOTIDE REPEATS;

EID: 14844314896     PISSN: 00223077     EISSN: None     Source Type: Journal    
DOI: 10.1152/jn.00308.2004     Document Type: Article

References (64)

1. Barria A and Malinow R. Subunit-specific NMDA receptor trafficking to synapses. Neuron 35: 345-353, 2002.
2. Bliss TV and Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361: 31-39, 1993.
3. Brimecombe JC, Boeckman FA, and Aizenman E. Functional consequences of NR2 subunit composition in single recombinant N-methyl-D-aspartate receptors. Proc Natl Acad Sci USA 94: 11019-11024, 1997.
4. Cepeda C, Ariano MA, Calvert CR, Flores-Hernandez J, Chandler SH, Leavitt BR, Hayden MR, and Levine MS. NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 66: 525-539, 2001.
5. Cepeda C, Hurst RS, Calvert CR, Hernandez-Echeagaray E, Nguyen OK, Jocoy E, Christian LJ, Ariano MA, and Levine MS. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 23: 961-969, 2003.
6. Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci 23: 387-392, 2000.
7. Chapman DE, Keefe KA, and Wilcox KS. Evidence for functionally distinct synaptic NMDA receptors in ventromedial versus dorsolateral striatum. J Neurophysiol 89: 69-80, 2003.
8. Chen N, Luo T, and Raymond LA. Subtype-dependence of NMDA receptor channel open probability. J Neurosci 19: 6844-6854, 1999a.
9. Chen N, Luo T, Wellington C, Metzler M, McCutcheon K, Hayden MR, and Raymond LA. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J Neurochem 72: 1890-1898, 1999b.
10. Christie JM, Jane DE, and Monaghan DT. Native N-methyl-D-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites. J Pharmacol Exp Ther 292: 1169-1174, 2000.
11. DiFiglia M. Excitotoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci 13: 286-289, 1990.
12. Dingledine R, Borges K, Bowie D, and Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 51: 7-61, 1999.
13. Donevan SD and McCabe RT. Conantokin G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors. Mol Pharmacol 58: 614-623, 2000.
14. Dunah AW and Standaert DG. Subcellular segregation of distinct heteromeric NMDA glutamate receptors in the striatum. J Neurochem 85: 935-943, 2003.
15. Flint AC, Maisch US, Weishaupt JH, Kriegstein AR, and Monyer H. NR2A subunit expression shortens NMDA receptor synaptic currents in developing neocortex. J Neurosci 17: 2469-2476, 1997.
16. Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, and Ellerby LM. Inhibition of calpain cleavage of Huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem, 2004.
17. Goellner GM and Rechsteiner M. Are Huntington's and polyglutamine-based ataxias proteasome storage diseases? Int J Biochem Cell Biol 35: 562-571, 2003.
18. Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, Hackam AS, Logvinova AV, Peel AL, Chen SF, Hook V, Singaraja R, Krajewski S, Goldsmith PC, Ellerby HM, Hayden MR, Bredesen DE, and Ellerby LM. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ 11: 424-428, 2004.
19. Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, and Hayden MR. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23: 181-192, 1999.
20. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-983, 1993.
21. Johnson JW and Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325: 529-531, 1987.
22. Joshi I and Andrew RD. Imaging anoxic depolarization during ischemia-like conditions in the mouse hemi-brain slice. J Neurophysiol 85: 414-424, 2001.
23. Kew JN, Richards JG, Mutel V, and Kemp JA. Developmental changes in NMDA receptor glycine affinity and ifenprodil sensitivity reveal three distinct populations of NMDA receptors in individual rat cortical neurons. J Neurosci 18: 1935-1943, 1998.
24. Klein RC, Prorok M, Galdzicki Z, and Castellino FJ. The amino acid residue at sequence position 5 in the conantokin peptides partially governs subunit-selective antagonism of recombinant N-methyl-D-aspartate receptors. J Biol Chem 276: 26860-26867, 2001.
25. Kochhar A, Zivin JA, Lyden PD, and Mazzarella V. Glutamate antagonist therapy reduces neurologic deficits produced by focal central nervous system ischemia. Arch Neurol 45: 148-153, 1988.
26. Kremer B, Weber B, and Hayden MR. New insights into the clinical features, pathogenesis and molecular genetics of Huntington disease. Brain Pathol 2: 321-335, 1992.
27. Kuppenbender KD, Albers DS, Iadarola MJ, Landwehrmeyer GB, and Standaert DG. Localization of alternatively spliced NMDAR1 glutamate receptor isoforms in rat striatal neurons. J Comp Neurol 415: 204-217, 1999.
28. Kuppenbender KD, Standaert DG, Feuerstein TJ, Penney JB Jr, Young AB, and Landwehrmeyer GB. Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum. J Comp Neurol 419: 407-421, 2000.
29. Kuryatov A, Laube B, Betz H, and Kuhse J. Mutational analysis of the glycine-binding site of the NMDA receptor: structural similarity with bacterial amino acid-binding proteins. Neuron 12: 1291-1300, 1994.
30. Landwehrmeyer GB, Standaert DG, Testa CM, Penney JB Jr, and Young AB. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci 15: 5297-5307, 1995.
31. Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME, Jokel ES, Carpenter EM, Zanjani H, Hurst RS, Efstratiadis A, Zeitlin S, and Chesselet MF. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 58: 515-532, 1999.
32. Li B, Otsu Y, Murphy TH, and Raymond LA. Developmental decrease in NMDA receptor desensitization associated with shift to synapse and interaction with postsynaptic density-95. J Neurosci 23: 11244-11254, 2003.
33. Li H, Wyman T, Yu ZX, Li SH, and Li XJ. Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. Hum Mol Genet 12: 2021-2030, 2003.
34. Li JH, Wang YH, Wolfe BB, Krueger KE, Corsi L, Stocca G, and Vicini S. Developmental changes in localization of NMDA receptor subunits in primary cultures of cortical neurons. Eur J Neurosci 10: 1704-1715, 1998.
35. Li L, Fan M, Icton CD, Chen N, Leavitt BR, Hayden MR, Murphy TH, and Raymond LA. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol Aging 24: 1113-1121, 2003.
36. Luo J, Wang Y, Yasuda RP, Dunah AW, and Wolfe BB. The majority of N-methyl-D-aspartate receptor complexes in adult rat cerebral cortex contain at least three different subunits (NR1/NR2A/NR2B). Mol Pharmacol 51: 79-86, 1997.
37. Monyer H, Burnashev N, Laurie DJ, Sakmann B, and Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12: 529-540, 1994.
38. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, and Greenamyre JT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5: 731-736, 2002.
39. Park CK, Nehls DG, Graham DI, Teasdale GM, and McCulloch J. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann Neurol 24: 543-551, 1988.
40. Philpot BD, Sekhar AK, Shouval HZ, and Bear MF. Visual experience and deprivation bidirectionally modify the composition and function of NMDA receptors in visual cortex. Neuron 29: 157-169, 2001.
41. Priestley T, Laughton P, Myers J, Le Bourdelles B, Kerby J, and Whiting PJ. Pharmacological properties of recombinant human N-methyl-D-aspartate receptors comprising NR1a/NR2A and NR1a/NR2B subunit assemblies expressed in permanently transfected mouse fibroblast cells. Mol Pharmacol 48: 841-848, 1995.
42. Rothstein JD, Martin LJ, and Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 326: 1464-1468, 1992.
43. Rothstein JD, Tsai G, Kuncl RW, Clawson L, Cornblath DR, Drachman DB, Pestronk A, Stauch BL, and Coyle JT. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 28: 18-25, 1990.
44. Rumbaugh G, Prybylowski K, Wang JF, and Vicini S. Exon 5 and spermine regulate deactivation of NMDA receptor subtypes. J Neurophysiol 83: 1300-1306, 2000.
45. Rutter AR, Freeman FM, and Stephenson FA. Further characterization of the molecular interaction between PSD-95 and NMDA receptors: the effect of the NR1 splice variant and evidence for modulation of channel gating. J Neurochem 81: 1298-1307, 2002.
46. Sans N, Petralia RS, Wang Y-X, Blahos II J, Hell JW, and Wenthold RJ. A developmental switch in NMDA receptor-associated proteins occurs at hippocampal synapses. Soc Neurosci Abst 25: 231, 1999.
47. Sheng M, Cummings J, Roldan LA, Jan YN, and Jan LY. Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature 368: 144-147, 1994.
48. Simon RP, Swan JH, Griffiths T, and Meldrum BS. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science 226: 850-852, 1984.
49. Song C, Zhang Y, Parsons CG, and Liu YF, Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-D-aspartate receptors. J Biol Chem 278: 33364-33369, 2003.
50. Srivastava R, Brouillet E, Beal MF, Storey E, and Hyman BT. Blockade of 1-methyl-4-phenytpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss. Neurobiol Aging 14: 295-301, 1993.
51. Stocca G and Vicini S. Increased contribution of NR2A subunit to synaptic NMDA receptors in developing rat cortical neurons. J Physiol 507: 13-24, 1998.
52. Sun Y, Savanenin A, Reddy PH, and Liu YF. Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem 276: 24713-24718, 2001.
53. Tovar KR and Westbrook GL. The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci 19: 4180-4188, 1999.
54. Turski L, Bressler K, Rettig KJ, Loschmann PA, and Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349: 414-418, 1991.
55. Umemiya M and Raymond LA. Dopaminergic modulation of excitatory postsynaptic currents in rat neostriatal neurons. J Neurophysiol 78: 1248-1255, 1997.
56. Vicini S, Wang JF, Li JH, Zhu WJ, Wang YH, Luo JH, Wolfe BB, and Grayson DR. Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors. J Neurophysiol 79: 555-566, 1998.
57. Vonsattel JP and DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 57: 369-384, 1998.
58. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, and Richardson EP, Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44: 559-577, 1985.
59. Wafford KA, Kathoria M, Bain CJ, Marshall G, Le Bourdelles B, Kemp JA, and Whiting PJ. Identification of amino acids in the N-methyl-D-aspartate receptor NR1 subunit that contribute to the glycine binding site. Mol Pharmacol 47: 374-380, 1995.
60. Williams K. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 44: 851-859, 1993.
61. Zeron MM, Chen N, Moshaver A, Lee AT, Wellington CL, Hayden MR, and Raymond LA. Mutant huntingtin enhances excitotoxic cell death. Mol Cell Neurosci 17: 41-53, 2001.
62. Zeron MM, Fernandes HB, Krebs C, Shehadeh J, Wellington CL, Leavitt BR, Baimbridge KG, Hayden MR, and Raymond LA. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol Cell Neurosci 25: 469-479, 2004.
63. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, and Raymond LA. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33: 849-860, 2002.
64. Zucker RS. Short-term synaptic plasticity. Annu Rev Neurosci 12: 13-31, 1989.